Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | GLA | P06280 | 2/20 | 0.67 |
| ▸ | F2 | P00734 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21988640 | 0.88 | ALDH1A1 (0.71) | ALDH1A1GLAF2HPGDPDE3B | |
| SCHEMBL27932593 | 0.84 | KMT2A (0.49) | ALDH1A1GLAF2HPGDNCEH1 | |
| SCHEMBL7590790 | 0.83 | ALDH1A1 (0.68) | ALDH1A1GLAF2HPGDPDE3B | |
| SCHEMBL3614403 | 0.83 | ALDH1A1 (0.50) | ALDH1A1GLAF2HPGDPDE3B | |
| SCHEMBL28814899 | 0.82 | ALDH1A1 (0.67) | ALDH1A1GLAF2HPGDPDE3B | |
| SCHEMBL23247889 | 0.81 | PDE3B (0.46) | ALDH1A1GLAF2HPGDPDE3B | |
| SCHEMBL7594210 | 0.81 | ALDH1A1 (0.62) | ALDH1A1GLAF2HPGDPDE3B | |
| SCHEMBL23247805 | 0.79 | ALDH1A1 (0.63) | ALDH1A1GLAF2HPGDPDE3B | |
| SCHEMBL25724501 | 0.79 | ALDH1A1 (0.43) | ALDH1A1GLAF2HPGDNCEH1 | |
| SCHEMBL621672 | 0.79 | PDGFRB (0.58) | ALDH1A1GLAF2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577258-B2 | Macrocyclic compound | VERNALIS (R&D) LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| EP-4223368-B1 | MACROCYCLIC COMPOUNDS INCORPORATING PIPERIDINE AND QUINOLINE OR QUNAXOLINE AS IRAK-4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | ASAHI KASEI PHARMA CORP (JP) | 2025-05-21 | — | — | EP | disclosed |
| CN-116348472-B | Macrocyclic compounds | 旭化成制药株式会社 | 2024-12-03 | — | — | CN | disclosed |
| US-20230357271-A1 | MACROCYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230357271-A1 | MACROCYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230357271-A1 | MACROCYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-11-09 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4223368-A1 | MACROCYCLE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2023-08-09 | — | — | EP | disclosed |
| WO-2013038362-A1 | 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4] TRIAZOLO [4, 3 -A] PYRADINES AS TYROSINE KINASE | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| EP-2084162-B1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2012107500-A1 | [1, 2, 4] TRIAZOLO [4, 3 -B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE | NOVARTIS AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| CN-102574853-A | Heterocyclic oxime compounds | NOVARTIS AG | 2012-07-11 | — | — | CN | disclosed |
| EP-2162132-A1 | HETEROCYCLIC KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-10-15 | — | — | US | disclosed |
| EP-2084162-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090156594-A1 | HETEROCYCLIC KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008144767-A1 | HETEROCYCLIC KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008051808-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577258-B2 | Macrocyclic compound | IRAK1, IRAK4, IRAK2 | ALDH1A1 2947/4885GLA 3442/4885F2 4852/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | ALDH1A1 3284/4885GLA 2140/4885F2 4784/4885 |
| US-20090156594-A1 | HETEROCYCLIC KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K13 | ALDH1A1 4524/4885GLA 4018/4885F2 4698/4885 |
| US-20230357271-A1 | MACROCYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | ALDH1A1 3370/4885GLA 3309/4885F2 4752/4885 |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | MAP3K20, TTK, PRKACB | ALDH1A1 4730/4885GLA 4529/4885F2 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.